Zhengnian Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/407609/publications.pdf

Version: 2024-02-01

		1307594	1372567	
11	537	7	10	
papers	citations	h-index	g-index	
12	12	12	787	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell, 2020, 183, 1714-1731.e10.	28.9	163
2	Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15. Nature Chemical Biology, 2020, 16, 7-14.	8.0	136
3	Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood, 2019, 133, 952-961.	1.4	117
4	Development and Characterization of a Wee1 Kinase Degrader. Cell Chemical Biology, 2020, 27, 57-65.e9.	5.2	68
5	A Concise Stereocontrolled Total Synthesis of (±)â€Stemoamide. Asian Journal of Organic Chemistry, 2014, 3, 52-54.	2.7	18
6	Identification of small molecule inhibitors targeting the Zika virus envelope protein. Antiviral Research, 2019, 164, 147-153.	4.1	14
7	Benzopyrimidodiazepinone inhibitors of TNK2. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126948.	2.2	7
8	Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. Bioorganic and Medicinal Chemistry Letters, 2022, 68, 128718.	2.2	7
9	Discovery of a series of benzopyrimidodiazepinone TNK2 inhibitors via scaffold morphing. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127456.	2.2	4
10	Synthesis and Structure–Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. European Journal of Medicinal Chemistry, 2022, 238, 114433.	5.5	3
11	Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies. Blood, 2018, 132, 263-263.	1.4	O